Publication: Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy (DMD) patients
This research article, published in the Journal of Comparative Effectiveness Research, provides results from a study investigating the efficacy of a mutation-specific therapy in delaying loss of ambulation (LoA) and respiratory function in patients with nonsense mutation DMD (nmDMD)
Learn about the demographics of patients enrolled in the long-term Phase 3 propensity score-matched study
Explore the data on age at LoA in the treated vs untreated populations
Understand the decline in lung function, as measured by reduction in predicted forced vital capacity to <60% across the 2 groups
McDonald CM, Muntoni F, Penematsa V, et al. J Comp Eff Res. 2021;11(3):139–155
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200033 | March 2022
Sign in or register to access exclusive content on this site